|
Canada-0-ESTATES ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Broader Adoption of SGLT2 Inhibitors in Clinical Practice
Over the past decade, the indications for sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney and cardiovascular risk reduction have expanded, driven by clinical trial evidence demonstrating their efficacy among individuals with chronic kidney disease (CKD), heart failure, diabetes, and
- Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase . . .
Bempedoic acid is a new drug that improves the control of cholesterol levels, either as monotherapy or in combination with existing lipid-lowering therapies, and shows clinical efficacy in cardiovascular disease patients Thus, patients with
- U. S. FDA Approves Broad New Labels for NEXLETOL and . . . - DAIC
April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention
- Esperion Showcases New Data from CLEAR Outcomes Highlighting . . .
In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture
- Evaluation of Major Cardiovascular Events in Participants . . .
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant
- Impact of SGLT2 Inhibitors on Mortality Across Different . . .
SGLT2 inhibitors as a class provide a consistent and significant reduction in all-cause mortality across both short-term (up to one year) and long-term follow-up, while the long-term benefit extends to chronic heart failure, CKD, and high-risk DM Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer glucose-lowering, cardio-protective and reno-protective properties Mortality rates
- Nexletol shows CLEAR benefit in cardiovascular outcome trial
New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
|
|